Full video transcriptClick to expand
Auto-generated transcript of @biohackwithbails's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Tessa Fensine, what it is, what it does, what are the benefits, and things that you can expect,
- 0:04especially when you implement this into your routine. First things first, what is Tessa Fensine? Tessa
- 0:08Fensine is a reuptake inhibitor, which plays a direct role with our neural transmitters, how they
- 0:13behave and how they communicate. And its main job is to turn down hunger by changing our brain
- 0:17chemistry. And how this actually works is it communicates to these neural transmitters such as
- 0:22serotonin, dopamine, and norepinephrine. And it only makes sense to really break down these
- 0:27neural transmitters. So the first one is dopamine, which is the I wanted chemical. And when dopamine
- 0:32is active, it makes you care about certain things. It makes you more motivated. It makes you more
- 0:37ambitious, which as we know is super, super important. Serotonin on the other hand is the I am satisfied
- 0:44chemical. And its primary role, especially when serotonin is balanced, is to help with
- 0:48fullness and to help with mood stability. So making you feel fuller, more satisfied, longer. And this
- 0:54is great for a lot of people who are specifically emotional eaters. And the last neural transmitter
- 0:59that Tessa Fensine really affects is norepinephrine. And that is the let's go chemical. And when norepinephrine
- 1:04is very prevalent within the body, it plays a direct role with our focus with our energy and even our
- 1:09metabolic system. And in the simplest terms, norepinephrine turns the lights on. And I'm sure
- 1:14you have the same question that I did. How is this really different than red to especially since it's
- 1:18really helping with my appetite suppression? The difference is is GLP works within the gut versus
- 1:23Tessa Fensine works within the brain. GLP slower the digestion and Tessa Fensines lowers the desire
- 1:28to consume. So what can you expect especially when you implement something like Tessa Fensine
- 1:32into your daily routine into your recipes, you can expect that your food noise will drastically
- 1:37decrease, which I think is really cool. But there's also really great benefits to especially when
- 1:40you're working with these neural transmitters, it's going to help with mood, it's going to help
- 1:43with cognitive focus, it's going to help with energy expenditure. And I forgot to mention this too,
- 1:48especially when it came to norepinephrine, there is a term called thermogenesis, which basically
- 1:52means a calorie burn. So in the simplest terms, your body is burning more calories to generate
- 1:57more heat, which is therefore thermogenesis. And the best benefits about thermogenesis is that it
- 2:01really helps burn body FAT at a rusted rate, which is really great. And obviously you can help boost
- 2:06your metabolism too, which results in better fuel usage rather than FAT just being stored back in
- 2:12the bond. So there's linsights goop into Tessa Fensine, why she's so amazing really breaking
- 2:16her down in the property is especially when it comes to these neural transmitters and how
- 2:19it's really different, comparative to something like ratatouille. If you guys have any questions
- 2:22at all, please let me know in the comments below. As always, I'm so happy to help. And I'm always
- 2:26happy that you are here.
GLP-1 'biohacking' claims on TikTok: what holds up?
Quick answer
Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin, norepinephrine) that reached Phase 2 clinical trials for weight management, with the TIPO-1 trial showing up to 10.6% body weight reduction at 1mg over 24 weeks but also dose-dependent increases in heart rate and blood pressure that raised safety concerns. It is not FDA-approved and is currently available only through compounding, meaning it lacks the regulatory oversight of branded medications. Patients with cardiovascular risk factors, hypertension, or psychiatric conditions should have a detailed clinical evaluation before any use.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 'biohacking' claims on TikTok: what holds up?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 'biohacking' claims on TikTok: what holds up? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 'biohacking' claims on TikTok: what holds up?" from Biohackwithbails. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin, norepinephrine) that reached Phase 2 clinical trials for weight management, with the TIPO-1 trial showing up to 10.
The reason this review is not generic is the source wording and the canonical claim label "glp1 tiktok 7611211500836883743." In this clip, the useful excerpt is: "Tessa Fensine, what it is, what it does, what are the benefits, and things that you can expect, especially when you implement this into your routine." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin, norepinephrine) that reached Phase 2 clinical trials for weight management, with the TIPO-1 trial showing up to 10.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin, norepinephrine) that reached Phase 2 clinical trials for weight management, with the TIPO-1 trial showing up to 10.6% body weight reduction at 1mg over 24 weeks but also dose-dependent increases in heart rate and blood pressure that raised safety concerns. It is not FDA-approved and is currently available only through compounding, meaning it lacks the regulatory oversight of branded medications. Patients with cardiovascular risk factors, hypertension, or psychiatric conditions should have a detailed clinical evaluation before any use.
- Tesofensine is not FDA-approved for any indication. It is available in the US only through compounding pharmacies, which are not subject to the same manufacturing and purity standards as regulated pharmaceutical products.
- The TIPO-1 trial (Astrup et al., 2008, The Lancet) found average heart rate increases of 7-8 bpm at therapeutic doses, a signal that effectively stalled Phase 3 development due to cardiovascular safety concerns.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tesofensine is not FDA-approved for any indication. It is available in the US only through compounding pharmacies, which are not subject to the same manufacturing and purity standards as regulated pharmaceutical products.
- The TIPO-1 trial (Astrup et al., 2008, The Lancet) found average heart rate increases of 7-8 bpm at therapeutic doses, a signal that effectively stalled Phase 3 development due to cardiovascular safety concerns.
- The triple reuptake mechanism is real and pharmacologically active, but presenting dopamine, serotonin, and norepinephrine effects as purely beneficial ignores that norepinephrine elevation carries blood pressure and cardiac rate risks.
- Retatrutide (the drug the creator called 'ratatouille') operates through GLP-1, GIP, and glucagon receptor agonism. It has a growing Phase 2 evidence base that is more recent and more robust than tesofensine's clinical data.
- Tesofensine's dopaminergic activity means it has a pharmacological profile that overlaps with compounds studied for addiction and dependence. This is not a benign supplement, and it should not be framed as one.
- Anyone considering tesofensine should have baseline cardiovascular assessment including resting heart rate and blood pressure monitoring throughout use, under the supervision of a licensed clinician.
- Compounded tesofensine is not equivalent to the pharmaceutical-grade compound used in clinical trials. Dose accuracy and formulation quality vary by compounding pharmacy and are not federally guaranteed.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @biohackwithbails actually say?
The creator made a case for tesofensine as a brain-based appetite suppressant, describing it as a triple reuptake inhibitor that affects dopamine, serotonin, and norepinephrine. She framed each neurotransmitter with a catchy label: dopamine as the "I wanted chemical," serotonin as the "I am satisfied chemical," and norepinephrine as the "let's go chemical." She also claimed tesofensine drives thermogenesis and distinguishes itself from GLP-1 drugs by working in the brain rather than the gut.
She repeatedly referred to the drug as "Tessa Fensine" and at one point compared it to "ratatouille" (meaning retatrutide, a GLP-1/GIP/glucagon tri-agonist). The comparison itself was reasonable in concept, even if the pronunciation made it hard to follow. She never mentioned dosing, which is notable given tesofensine has a very narrow therapeutic window.
Does the science back this up?
The core pharmacology is broadly accurate. Tesofensine is a triple monoamine reuptake inhibitor. The clinical trial record, however, is thin and complicated. The TIPO-1 trial (Astrup et al., 2008, The Lancet) showed meaningful weight loss at 0.5mg and 1mg doses but significant cardiovascular side effects including elevated heart rate and blood pressure. That safety data is completely absent from this video.
The neurotransmitter descriptions are simplified but not wildly wrong. Dopamine does play a role in reward-motivated eating behavior, as shown in research by Wang et al. (2001, The Lancet) linking dopamine D2 receptor availability to obesity. Serotonin's role in satiety is well-supported, particularly through 5-HT2C receptor pathways. Norepinephrine does contribute to thermogenesis via beta-adrenergic receptor activation in brown adipose tissue (Cannon and Nedergaard, 2004, Physiological Reviews). The problem is the video presents these mechanisms as clean and tidy when the reality is far more complicated and the side effect implications are ignored entirely.
What did they get wrong (or right)?
Credit where it is due: the GLP-1 versus tesofensine distinction is actually a reasonable one. GLP-1 agonists primarily slow gastric emptying and act on peripheral and central GLP-1 receptors to reduce appetite. Tesofensine works primarily through central monoaminergic pathways. Framing this as "gut versus brain" is oversimplified but not inaccurate as a starting point.
What is genuinely wrong or incomplete here is significant. First, calling norepinephrine activity purely beneficial ignores that it also raises heart rate and blood pressure, which is exactly why tesofensine's development stalled after Phase 2. Second, the thermogenesis description is technically real but framed as a bonus feature rather than a mechanism with cardiovascular cost. Third, the claim that tesofensine will "drastically decrease" food noise implies a certainty the clinical data does not support at safe doses. And fourth, comparing it favorably to retatrutide without noting that retatrutide has a substantially larger and more recent clinical evidence base is misleading by omission.
What should you actually know?
Tesofensine is not FDA-approved. It is available through compounding pharmacies in some markets, which means formulation, purity, and dosing consistency are not federally regulated the way branded medications are. Compounded tesofensine is not the same as a pharmaceutical-grade product from a clinical trial.
The TIPO-1 trial data showed that even modest doses produced clinically meaningful increases in heart rate, roughly 7 to 8 beats per minute on average. For someone with underlying cardiovascular risk factors, that is not a trivial number. Anyone using this compound should be under the supervision of a licensed clinician who can monitor cardiovascular markers, and that context is entirely absent from this video.
The neurotransmitter framing also matters because triple reuptake inhibitors affecting dopaminergic pathways carry dependency and abuse potential considerations that deserve mention. This is not a supplement. It is a pharmacologically active compound with a history of being investigated as an antidepressant before being repurposed for obesity.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Biohackwithbails · TikTok creator
6.3K views on this video
GLP-1 'biohacking' claims on TikTok: what holds up?
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tesofensine?
Tesofensine is not FDA-approved for any indication. It is available in the US only through compounding pharmacies, which are not subject to the same manufacturing and purity standards as regulated pharmaceutical products.
What does the video say about the tipo-1 trial (astrup et al., 2008, the lancet) found?
The TIPO-1 trial (Astrup et al., 2008, The Lancet) found average heart rate increases of 7-8 bpm at therapeutic doses, a signal that effectively stalled Phase 3 development due to cardiovascular safety concerns.
What does the video say about the triple reuptake mechanism?
The triple reuptake mechanism is real and pharmacologically active, but presenting dopamine, serotonin, and norepinephrine effects as purely beneficial ignores that norepinephrine elevation carries blood pressure and cardiac rate risks.
What does the video say about retatrutide (the drug the creator called 'ratatouille') operates through glp-1,?
Retatrutide (the drug the creator called 'ratatouille') operates through GLP-1, GIP, and glucagon receptor agonism. It has a growing Phase 2 evidence base that is more recent and more robust than tesofensine's clinical data.
What does the video say about tesofensine's dopaminergic activity means it has a pharmacological profile?
Tesofensine's dopaminergic activity means it has a pharmacological profile that overlaps with compounds studied for addiction and dependence. This is not a benign supplement, and it should not be framed as one.
What does the video say about anyone considering tesofensine should have baseline cardiovascular assessment including resting?
Anyone considering tesofensine should have baseline cardiovascular assessment including resting heart rate and blood pressure monitoring throughout use, under the supervision of a licensed clinician.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Biohackwithbails, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.